---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-011031"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2023-06-13T23:59:59+00:00"
generated_at: "2026-06-14T02:18:56.833900+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics stockholders elect three Class II directors, ratify Ernst & Young as auditor

## Summary
- Daniel Curran, Robert Ross, and Yuan Xu elected as Class II directors for three-year terms through 2026.
- Ratification of Ernst & Young as independent auditor for FY 2023: 21,955,354 for, 1,623 against, 230,537 abstain.
- Broker non-votes of 3,812,216 recorded on each director election.
- Annual meeting held June 8, 2023; all proposals passed with strong support.

## SEC filing metadata
- accession: 0001558370-23-011031
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2023-06-13T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837023011031/0001558370-23-011031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837023011031/xlo-20230608x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-011031
- JSON: https://secwatch.observer/filing/0001558370-23-011031.json
- Plain text: https://secwatch.observer/filing/0001558370-23-011031.txt

## Key facts
- Shareholder Votes
  Xilio Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-08 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-08
  source text: 2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837023011031/0001558370-23-011031-index.htm
- Shareholder Votes
  Xilio Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2023-06-08 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-08
  source text: 1. The Company’s stockholders elected Daniel Curran, M.D., Robert Ross, M.D., and Yuan Xu, Ph.D., as Class II directors, each to serve for a three-year term expiring at the 2026 annual meeting of stockholders and until his or her successor has been duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837023011031/0001558370-23-011031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.